Dual Bronchodilator in the Era of Triple Therapy

References

• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2020 Available from: http://www.goldcopd.org. Accessed 220,2020.
   Google Scholar
• CelliBR. Pharmacological therapy of COPD: reasons for optimism. Chest. 2018;154(6):1404–1415. doi:10.1016/j.chest.2018.07.00530028967
   PubMed Web of Science ®Google Scholar
• SinghD, AgustiA, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5). doi:10.1183/13993003.00164-2019.
   Web of Science ®Google Scholar
• CalverleyPMA, AnzuetoAR, CarterK, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi:10.1016/S2213-2600(18)30102-429605624
   PubMed Web of Science ®Google Scholar
• CelliB, CraterG, KilbrideS, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991. doi:10.1378/chest.13-157924385182
   PubMed Web of Science ®Google Scholar
• DonohueJF, Maleki-YazdiMR, KilbrideS, MehtaR, KalbergC, ChurchA. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.00123830094
   PubMed Web of Science ®Google Scholar
• DecramerM, AnzuetoA, KerwinE, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. doi:10.1016/S2213-2600(14)70065-724835833
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMR, KaelinT, RichardN, ZvarichM, ChurchA. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–1760. doi:10.1016/j.rmed.2014.10.00225458157
   PubMed Web of Science ®Google Scholar
• BuhlR, MaltaisF, AbrahamsR, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.0013601425573406
   PubMed Web of Science ®Google Scholar
• MartinezFJ, RabeKF, FergusonGT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–357. doi:10.1016/j.chest.2016.11.02827916620
   PubMed Web of Science ®Google Scholar
• HananiaNA, TashkinDP, KerwinEM, et al. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel co-suspension delivery technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;126:105–115. doi:10.1016/j.rmed.2017.03.01528427541
   PubMed Web of Science ®Google Scholar
• MahlerDA, KerwinE, AyersT, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(9):1068–1079. doi:10.1164/rccm.201505-1048OC26177074
   PubMed Web of Science ®Google Scholar
• BatemanED, FergusonGT, BarnesN, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494. doi:10.1183/09031936.0020021223722616
   PubMed Web of Science ®Google Scholar
• FergusonGT, TaylorAF, ThachC, et al. Long-term maintenance bronchodilation with indacaterol/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT 3 study. Chronic Obstr Pulm Dis. 2016;3(4):716–728.28848898
   PubMedGoogle Scholar
• WedzichaJA, DecramerM, FickerJH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209. doi:10.1016/S2213-2600(13)70052-324429126
   PubMed Web of Science ®Google Scholar
• SinghD, JonesPW, BatemanED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;18(14):178. doi:10.1186/1471-2466-14-178
   Web of Science ®Google Scholar
• CalverleyPM, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• CalverleyP, PauwelsR, VestboJ, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456. doi:10.1016/S0140-6736(03)12459-212583942
   PubMed Web of Science ®Google Scholar
• CalverleyPM, BoonsawatW, CsekeZ, ZhongN, PetersonS, OlssonH. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–919. doi:10.1183/09031936.03.0002700314680078
   PubMed Web of Science ®Google Scholar
• SzafranskiW, CukierA, RamirezA, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81. doi:10.1183/09031936.03.0003140212570112
   PubMed Web of Science ®Google Scholar
• DonohueJF, WorsleyS, ZhuCQ, HardakerL, ChurchA. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–881. doi:10.1016/j.rmed.2015.04.01826006754
   PubMed Web of Science ®Google Scholar
• RodrigoGJ, PlazaV. Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review. Chest. 2014;146(2):309–317. doi:10.1378/chest.13-280724556877
   PubMed Web of Science ®Google Scholar
• SinghD, WorsleyS, ZhuCQ, HardakerL, ChurchA. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;19(15):91. doi:10.1186/s12890-015-0092-1
   Web of Science ®Google Scholar
• VogelmeierCF, BatemanED, PallanteJ, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60. doi:10.1016/S2213-2600(12)70052-824321804
   PubMed Web of Science ®Google Scholar
• ZhongN, WangC, ZhouX, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015–1026.26082625
   PubMed Web of Science ®Google Scholar
• WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• CazzolaM, RoglianiP, CalzettaL, MateraMG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52(6). doi:10.1183/13993003.01586-2018
   Web of Science ®Google Scholar
• SinghD, PapiA, CorradiM, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X27598678
   PubMed Web of Science ®Google Scholar
• PapiA, KostikasK, WedzichaJA, et al. Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME study. Am J Respir Crit Care Med. 2018;197(9):1223–1226. doi:10.1164/rccm.201709-1822LE29099609
   PubMed Web of Science ®Google Scholar
• VestboJ, PapiA, CorradiM, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-528385353
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnacleH, BirkR, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC28375647
   PubMed Web of Science ®Google Scholar
• BremnerPR, BirkR, BrealeyN, IsmailaAS, ZhuCQ, LipsonDA. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19(1):19. doi:10.1186/s12931-018-0724-029370819
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• FergusonGT, RabeKF, MartinezFJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758.30232048
   PubMed Web of Science ®Google Scholar
• RabeKF, MartinezFJ, FergusonGT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;24.32609980
   PubMed Web of Science ®Google Scholar
• O’DonnellDE, FlügeT, GerkenF, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840. doi:10.1183/09031936.04.0011600415218994
   PubMed Web of Science ®Google Scholar
• O’DonnellDE, SciurbaF, CelliB, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130(3):647–656. doi:10.1378/chest.130.3.64716963658
   PubMed Web of Science ®Google Scholar
• TashkinDP, CelliB, SennS, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa080580018836213
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, WedzichaJA. COPD exacerbations.1: epidemiology. Thorax. 2006;61(2):164–168. doi:10.1136/thx.2005.04180616443707
   PubMed Web of Science ®Google Scholar
• MagnussenH, DisseB, Rodriguez-RoisinR, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa140715425196117
   PubMed Web of Science ®Google Scholar
• BeehKM, BurgelPR, FranssenFME, et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2017;196(2):139–149. doi:10.1164/rccm.201609-1794CI27922741
   PubMed Web of Science ®Google Scholar
• SuissaS, Dell’AnielloS, ErnstP. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice. Chest. 2020;157(4):846–855. doi:10.1016/j.chest.2019.11.00731759966
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJ, Martínez-GarcíaMA, Román SánchezP, SalcedoE, NavarroM, OchandoR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• FusoL, IncalziRA, PistelliR, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med. 1995;98(3):272–277. doi:10.1016/S0002-9343(99)80374-X7872344
   PubMed Web of Science ®Google Scholar
• BeehKM, DeromE, Echave-SustaetaJ, et al. The lung function profile of once-daily tiotropium and olodaterol via respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via accuhaler(®) (ENERGITO(®) study. Int J Chron Obstruct Pulmon Dis. 2016;11:193–205. doi:10.2147/COPD.S9505526893551
   PubMed Web of Science ®Google Scholar
• VogelmeierC, PaggiaroPL, DorcaJ, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48(4):1030–1039. doi:10.1183/13993003.00216-201627492833
   PubMed Web of Science ®Google Scholar
• ChapmanKR, HurstJR, FrentSM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC29779416
   PubMed Web of Science ®Google Scholar
• WatzH, TetzlaffK, WoutersEF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/S2213-2600(16)00100-427066739
   PubMed Web of Science ®Google Scholar
• JonesPW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56(11):880–887. doi:10.1136/thorax.56.11.88011641515
   PubMed Web of Science ®Google Scholar
• CrimC, CalverleyPM, AndersonJA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–647. doi:10.1183/09031936.0019390819443528
   PubMed Web of Science ®Google Scholar
• DrummondMB, DasenbrookEC, PitzMW, MurphyDJ, FanE. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(20):2407–2416. doi:10.1001/jama.2008.71719033591
   PubMed Web of Science ®Google Scholar
• MorjariaJB, RigbyA, MoriceAH. Inhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT study. Lung. 2017;195(3):281–288. doi:10.1007/s00408-017-9990-828255905
   PubMed Web of Science ®Google Scholar
• ErnstP, GonzalezAV, BrassardP, SuissaS. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162–166.17400730
   PubMed Web of Science ®Google Scholar
• CrimC, CalverleyPMA, AndersonJA, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: the SUMMIT trial. Respir Med. 2017;131:27–34. doi:10.1016/j.rmed.2017.07.06028947039
   PubMed Web of Science ®Google Scholar
• CrimC, DransfieldMT, BourbeauJ, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12(1):27–34. doi:10.1513/AnnalsATS.201409-413OC25490706
   PubMed Web of Science ®Google Scholar
• PavordID, LettisS, AnzuetoA, BarnesN. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016;4(9):731–741. doi:10.1016/S2213-2600(16)30148-527460163
   PubMed Web of Science ®Google Scholar
• SinghS, AminAV, LokeYK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219–229. doi:10.1001/archinternmed.2008.55019204211
   PubMed Web of Science ®Google Scholar
• JansonC, StratelisG, Miller-LarssonA, HarrisonTW, LarssonK. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3055–3064. doi:10.2147/COPD.S14365629089754
   PubMed Web of Science ®Google Scholar
• KewKM, SeniukovichA. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;10(3):CD010115.
   Google Scholar
• Martinez-GarciaMA, FanerR, OsculloG, et al. Inhaled steroids, circulating eosinophils, chronic airway infection and pneumonia risk in chronic obstructive pulmonary disease: a network analysis. Am J Respir Crit Care Med. 2020;201(9):1078–1085. doi:10.1164/rccm.201908-1550OC31922913
   PubMed Web of Science ®Google Scholar
• HartleyBF, BarnesNC, LettisS, ComptonCH, PapiA, JonesP. Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2020;21(1):5. doi:10.1186/s12931-019-1262-031907054
   PubMed Web of Science ®Google Scholar
• BalbiB, AufieroA, PesciA, et al. Lower respiratory tract inflammation in chronic bronchitis. Evaluation by bronchoalveolar lavage and changes associated with treatment with immucytal, a biological response modifier. Chest. 1994;106(3):819–826. doi:10.1378/chest.106.3.8198082365
   PubMed Web of Science ®Google Scholar
• KeatingsVM, BarnesPJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med. 1997;155(2):449–453. doi:10.1164/ajrccm.155.2.90321779032177
   PubMed Web of Science ®Google Scholar
• PapiA, RomagnoliM, BaraldoS, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(5):1773–1777. doi:10.1164/ajrccm.162.5.991011211069811
   PubMed Web of Science ®Google Scholar
• SivaR, GreenRH, BrightlingCE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906–913. doi:10.1183/09031936.0014630617301099
   PubMed Web of Science ®Google Scholar
• NegewoNA, McDonaldVM, BainesKJ, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1495–1504. doi:10.2147/COPD.S10033827445469
   PubMed Web of Science ®Google Scholar
• HastieAT, MartinezFJ, CurtisJL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967. doi:10.1016/S2213-2600(17)30432-029146301
   PubMed Web of Science ®Google Scholar
• SinghD, KolsumU, BrightlingCE, LocantoreN, AgustiA, Tal-SingerR. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. doi:10.1183/09031936.0016241425323230
   PubMed Web of Science ®Google Scholar
• Vedel-KroghS, NielsenSF, LangeP, VestboJ, NordestgaardBG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The copenhagen general population study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC26641631
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, KostikasK, FangJ, et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20(1):178. doi:10.1186/s12931-019-1130-y31391053
   PubMed Web of Science ®Google Scholar
• EltboliO, BrightlingCE. Eosinophils as diagnostic tools in chronic lung disease. Expert Rev Respir Med. 2013;7(1):33–42.
   PubMed Web of Science ®Google Scholar
• ChalmersJD, LaskaIF, FranssenFME, et al. Withdrawal of inhaled corticosteroids in COPD: a European respiratory society guideline. Eur Respir J. 2020;55(6):2000351. doi:10.1183/13993003.00351-202032366483
   PubMed Web of Science ®Google Scholar
• MateraMG, CardaciV, CazzolaM, RoglianiP. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14(4):533–541. doi:10.1517/14740338.2015.100136325557156
   PubMed Web of Science ®Google Scholar
• SuissaS, PatenaudeV, LapiF, ErnstP. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036. doi:10.1136/thoraxjnl-2012-20287224130228
   PubMed Web of Science ®Google Scholar
• PascoeS, LocantoreN, DransfieldMT, BarnesNC, PavordID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442. doi:10.1016/S2213-2600(15)00106-X25878028
   PubMed Web of Science ®Google Scholar
• SiddiquiSH, GuasconiA, VestboJ, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525. doi:10.1164/rccm.201502-0235LE26051430
   PubMed Web of Science ®Google Scholar
• RocheN, ChapmanKR, VogelmeierCF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Am J Respir Crit Care Med. 2017;195(9):1189–1197. doi:10.1164/rccm.201701-0193OC28278391
   PubMed Web of Science ®Google Scholar
• BafadhelM, McKennaS, TerryS, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55. doi:10.1164/rccm.201108-1553OC22447964
   PubMed Web of Science ®Google Scholar
• HindsDR, DiSantostefanoRL, LeHV, PascoeS. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open. 2016;6(6):e010099. doi:10.1136/bmjopen-2015-010099
   PubMed Web of Science ®Google Scholar
• FergusonGT, PapiA, AnzuetoA, et al. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. Eur Respir J. 2018;52(3):1801334. doi:10.1183/13993003.01334-201830220648
   PubMed Web of Science ®Google Scholar
• BafadhelM, SinghD, JenkinsC, et al. Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. Respir Res. 2020;21(1):17. doi:10.1186/s12931-020-1280-y31924197
   PubMed Web of Science ®Google Scholar
• BafadhelM, PetersonS, De BlasMA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-729331313
   PubMed Web of Science ®Google Scholar
• PascoeS, BarnesN, BrusselleG, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756.31281061
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, TetzlaffK, VogelmeierC, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(9):1219–1221. doi:10.1164/rccm.201612-2525LE28306321
   PubMed Web of Science ®Google Scholar
• WinkelP, StatlandBE, SaundersAM, OsbornH, KuppermanH. Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am J Clin Pathol. 1981;75(5):693–700. doi:10.1093/ajcp/75.5.6937234755
   PubMed Web of Science ®Google Scholar
• SchumannDM, TammM, KostikasK, StolzD. Stability of the blood eosinophilic phenotype in stable and exacerbated COPD. Chest. 2019;29.
   Web of Science ®Google Scholar
• OshagbemiOA, BurdenAM, BraekenDCW, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med. 2017;195(10):1402–1404. doi:10.1164/rccm.201701-0009LE28165763
   PubMed Web of Science ®Google Scholar
• MensingaTT, SchoutenJP, WeissST, Van der LendeR. Relationship of skin test reactivity and eosinophilia to level of pulmonary function in a community-based population study. Am Rev Respir Dis. 1992;146(3):638–643. doi:10.1164/ajrccm/146.3.6381519840
   PubMed Web of Science ®Google Scholar
• LandisSH, SurukiR, HiltonE, ComptonC, GalweyNW. Stability of blood eosinophil count in patients with COPD in the UK clinical practice research datalink. COPD. 2017;14(4):382–388. doi:10.1080/15412555.2017.131382728569614
   PubMedGoogle Scholar
• KreindlerJL, WatkinsML, LettisS, Tal-SingerR, LocantoreN. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naive patients with COPD. BMJ Open Respir Res. 2016;3(1):e000151. doi:10.1136/bmjresp-2016-000151
   PubMed Web of Science ®Google Scholar
• CalverleyPMA. A light in the darkness? The FLAME trial, blood eosinophils, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(9):1125–1127. doi:10.1164/rccm.201703-0560ED28459328
   PubMed Web of Science ®Google Scholar
• BloomCI, ElkinSL, QuintJK. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. Int J Chron Obstruct Pulmon Dis. 2019;14:279–287. doi:10.2147/COPD.S19008630774325
   PubMed Web of Science ®Google Scholar
• CorradoA, RossiA. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106(7):989–997. doi:10.1016/j.rmed.2012.03.00822483189
   PubMed Web of Science ®Google Scholar